v3.25.2
LONG-TERM LOANS
6 Months Ended
Jun. 30, 2025
Debt Disclosure [Abstract]  
LONG-TERM LOANS

NOTE 12 — LONG-TERM LOANS

 

As of June 30, 2025 and December 31, 2024, the Company’s long-term loans from banks and other financial institution consist of the following:

 

Indebtedness 

Weighted

Average

Interest

Rate*

  

Weighted

Average

Years to

Maturity*

  

June 30,

2025

  

December 31,

2024

 
Guaranteed loans                    
Fixed rate loan   0.01%   0.03   $80,824   $90,274 
Variable rate loans   1.19%   2.39    7,020,102    6,473,490 
Subtotal   1.20%   2.42    7,100,926    6,563,764 
                     
Unsecured loan                    
Fixed rate loan               35,742 
Subtotal               35,742 
                     
Total long-term loans   1.20%   2.42    7,100,926    6,599,506 
                     
Less: current portion             (69,420)   (96,824)
Non-current portion            $7,031,506   $6,502,682 

 

* Pertained to information for loans outstanding as of June 30, 2025.

 

The Company borrowed loans from various banks and a financial institution for working capital purposes.

 

Interest expense was $46,674 and $7,424 for the three months ended June 30, 2025 and 2024, respectively, and $50,635 and $10,432 for the six months ended June 30, 2025 and 2024, respectively.

 

The guarantee information of the Company’s outstanding loans as of June 30, 2025 and December 31, 2024 consists of the following:

 

  

June 30,

2025

  

December 31,

2024

 
Co-guaranteed by CEO of subsidiaries within the Company’s organizational structure and Tokyo Credit Guarantee Association  $164,430   $185,766 
Guaranteed by a subsidiary within the Company’s organizational structure  $6,936,496   $6,377,998 

 

As of June 30, 2025, future minimum payments for long-term loans are as follows:

 

Years ending December 31, 

Principal

Repayment

 
Remaining of 2025  $31,818 
2026   69,420 
2027   6,999,688 
Thereafter    
Total  $7,100,926 

 

 

SBC MEDICAL GROUP HOLDINGS INCORPORATED

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS